As a result, these inhibitors are prone to resistance and fail to address the immunosuppressive effects mediated by DDR1’s extracellular non-enzymatic domain, limiting their efficacy in achieving complete tumor regression within the complex tumor microenvironment. Here, DDR1 is linked to neoplasm.